Prevention of venous thrombo-embolic disease in medical patients;Prevention de la maladie thromboembolique veineuse en milieu medical

Sang Thrombose Vaisseaux

Volumn 9, Issue 1, 1997, Pages 15-21

  Herve L L ^a   Courtois, Vesque Hubert ^a  

^a Dept de Médecine Interne Ctr Hosp Univ Rouen Boisguillaume   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; DANAPAROID; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; WARFARIN;

DRUG EFFICACY; HUMAN; REVIEW; THROMBOEMBOLISM; THROMBOSIS PREVENTION; VEIN THROMBOSIS;

EID: 12644295058     PISSN: 09997385     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients : are we detecting enough deep vein thrombosis? J R Soc Med 1989 ; 82 : 203-5.
2. Lindblad B, Sternby NH, Bergqvist D. Incidence of venous thromboembolism verified by necropsy over 30 years. Br Med J 1991 ; 302 : 709-11.
3. Morgenthaler TI, Ryu JH. Clinical characteristics of fatal pulmonary embolism in a referral hospital. Mayo Clin Proc 1995 ; 70 : 417-24.
4. Clagett GP Anderson FA, Heit J, Levine MN, Wheeler HB. Fourth ACCP consensus conference on antithrombotic therapy. Prevention of venous thromboembolism. Chest 1995 ; 108 (suppl. 4) : 5312-34.
5. Leizorovicz A, Haugh MC, Chapuis FR, Samama MM, Boissel JP. Low molecular weight heparin in prevention of perioperative thrombosis. Br Med J 1992 ; 305 : 913-20.
6. Warlow C, Beattie AG, Terry G, et al. A double-blind trial of low closes of subcutaneous heparin in prevention of deep-vein thrombosis after myocardial infarction. Lancet 1973 ; i : 934-6.
7. Turpie AGG, Gent M Côte R, et al. A low-molecular weight heparinoid compared with unfractionated heparin in prevention of deep vein thrombosis in patients with acute ischemic stroke. A randomized, double-blind study. Ann Intern Med 1992 ; 117 : 353-7.
8. Gardlund B, for the Heparin Prophylaxis Study Group. Randomised, controlled trial of low-dose heparin for prevention of fatal embolism in patients with infectious diseases. Lancet 1996 ; 347 : 1357-61.
9. Nicolaides AN, for the European Consensus Statement. Prevention of venous thromboembolism. Int Angiol 1992 ; 11 : 151-9.
10. Thromboembolic Risk Factors (THRIFT) Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. Br Med J 1992 ; 305 : 567-74
11. Goldhaber SZ, Savage DD, Garrison RJ, et al. Risk factors for pulmonary embolism ; the Framingham Study. Am J Leo 1983 ; 74 : 1023-8.
12. Cogo A, Bernardi E, Prandoni P, et al. Acquired risk factors for deep-vein thrombosis in symptomatic outpatients. Arch Intern Med 1994 ; 154 : 164-8.
13. Janssen HF, Schachner J, Murray WJG. The risk of deep vein thrombosis. A computerized epidemiologic approach. Surgery 1985 ; 72 : 786-91.
14. Dahan R, Houlbert D, Caulin E. Prevention of deep vein thrombosis in elderly medical patients by a molecular weight heparin : a randomized double blind trial. Haemostasis 1986 ; 16 : 159-64.
15. Lévesque H, Borg JY, Courtois H. Le risque vasculaire des pilules contraceptives de troisième génération. J Mal Vasc 1997 (à paraître).
16. Lévesque H, Cailleux N, Courtois H. Hormonothérapie substitutive de la ménopause, hémostase et risque thromboembolique. J Mal Vasc 1994 ; 19 : 93-7.
17. Beyth RJ, Cohen AM, Landefeld S. Long-term outcomes of deep-vein thrombosis. Arch Intern Med 1995 ; 155 : 1031-7.
18. Nachman RL, Silverstein R. Hypercoagulable states. Ann Intern Med 1993 ; 119 : 819-27.
19. Love PE, Santoro SA. Antiphospholipid antibodies : anticardiolipin and me lupus anticoagulant in the systemic erytnematosus (SLE) and in non SLE disorders. Ann Intern Med 1990 ; 112 : 682-98.
20. Kierkegaard A, Norgren L. Graduated compression stockings in the prevention of deep vein thrombosis in patients with acute myocardial infarction. Eur Heart J 1993 ; 14 : 1365-8.
21. Turpie AGG, Levine MN, Hirsh J, et al. Double-blind randomized trial of org 10172 low-molecular-weight heparinoid prevention of deep-vein thrombosis in thrombotic stroke. Lancet 1987 ; i : 523-6.
22. Bern MM, Lokich JJ, Wallach SR, et al. Very low doses of warfarin can prevent thrombosis in central vein catheters : a randomized prospective trial. Ann Intern Med 1990 ; 112 : 423-8.
23. Monreal M, Alastrue A, et al. Upper extremity deep vein thrombosis in cancer patients with venous access devices-prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 1996 ; 75 : 251-3.
24. Levine M, Gent M, Arnold A, et al. Double-blind randomised trial very-low warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994 ; 343 : 886-9.
25. Belch JJ, Lowe GDO, Ward AG, et al. Prevention of deep vein thrombosis in medical patients with low-dose heparin. Scott Med J 1981 ; 26 : 115-7.
26. Halkin H, Goldberg J, Modan M, Modan B. Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis. Ann Intern Med 1982 ; 96 : 561-5.
27. Harenberg J, Kallenbach B, Martin U. et al. Randomized controlled study of heparin and low molecular weight heparin for prevention of deep vein thrombosis in medical patients, Thromb Res 1990 ; 59 : 639-50.
28. Bergmann JF, Neuhart E. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. Thromb Haemost 1996 ; 76 : 529-34.
29. Forette B, Wolmark Y. Nadroparine calcique dans la prévention de la maladie thromboembolique chez le sujet âgé. Étude de la tolérance. Presse Med 1995 ; 24 : 567-71.
30. Keller F, Flosbach CW and the PRIME Study Group. A randomized multicenter study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilized medical patients. Thromb Haemost 1995 ; 73 : 1106 (abstract 788).